Quintiles Announces Proposed Refinancing of Existing Indebtedness RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)

Announces Proposed Refinancing of Existing Indebtedness

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--April 29, 2015--Quintiles

Transnational Holdings Inc. (the "Company" or "Quintiles") (NYSE: Q)

announced today that it is proposing, subject to market and other

conditions, to enter into $1.75 billion of new senior secured credit

facilities consisting of a $500 million revolving credit facility and

$1.25 billion of term loans, and to issue $800 million aggregate

principal amount of unsecured debt. The Company intends to use the net

proceeds of the offering of the unsecured debt, together with the new

term loans, to refinance its existing credit facilities, as well as for

general corporate purposes, including corporate transactions and equity

repurchases. The refinancing transactions would be entered by Quintiles

Transnational Corp., the Company's wholly-owned subsidiary.

The Company cannot provide any assurances about the timing, terms or

interest rate associated with the planned refinancing, or that the

refinancing transactions can be completed at all.

This announcement shall not constitute an offer to sell or the

solicitation of an offer to buy any securities. Any such securities have

not been, and will not be, registered under the Securities Act of 1933,

as amended (the "Securities Act"), or any state securities laws, and may

not be offered or sold in the United States absent registration or an

applicable exemption from the registration requirements of the

Securities Act and applicable state securities law.

Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of Section 27A of the Securities Act and Section 21E of the

Securities Exchange Act of 1934, as amended. Such forward-looking

statements reflect, among other things, our current expectations

regarding a proposed refinancing, which are subject to known and unknown

risks, uncertainties and other factors that may cause actual results to

differ materially from those expressed or implied by such

forward-looking statements. Any statements contained herein that are not

statements of historical fact may be forward-looking statements and

should be evaluated as such. Without limiting the foregoing, the words

"anticipates," "believes," "estimates," "expects," "intends," "may,"

"plans," "projects," "should," "targets," "will" and the negative

thereof and similar words and expressions are intended to identify

forward-looking statements. Actual results may differ materially from

our expectations due to a number of factors, including changes in market

conditions and our ability to complete the proposed refinancing on the

terms described or at all. For a further discussion of the risks

relating to our business, see the "Risk Factors" section in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2014, filed

with the SEC, as such factors may be amended or updated from time to

time in our periodic filings with the SEC, which are accessible on the

SEC's website at www.sec.gov. These factors should not

be construed as exhaustive and should be read in conjunction with the

other cautionary statements that are included in this release and in the

Company's filings with the SEC. The Company assumes no obligation to

update any such forward-looking statement after the date of this

release, whether as a result of new information, future developments or

Quintiles (NYSE: Q), a Fortune 500 company, is the world's largest

provider of biopharmaceutical development and commercial outsourcing

services. With a network of more than 33,000 employees conducting

business in approximately 100 countries, we helped develop or

commercialize all of 2014's top-75 best-selling drugs on the market.

Quintiles applies the breadth and depth of our service offerings along

with extensive therapeutic, scientific and analytics expertise to help

our customers navigate an increasingly complex healthcare environment as

they seek to improve efficiency and effectiveness in the delivery of

better healthcare outcomes.

Click here to subscribe to Mobile Alerts for Quintiles.

Quintiles Transnational Holdings Inc.

Bridges, +1-919-998-1653

Mobile: +1-919-457-6347

Karl Deonanan, +1-919-998-2789